Coronavirus Resource Center

  • The Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services has been provided with $2B through the CARES Act to invest in research and development of vaccines, therapeutics, and diagnostics to combat COVID-19. BARDA is pursuing the following: vaccines, diagnostics, potential therapeutics, ventilators, immunomodulators or therapeutics targeting lung repair, pre and post-exposure prophylaxis, and respiratory protective devices.
  • BARDA DRIVe Accelerator: BARDAs Division of Research, Innovation, and Ventures (DRIVe) provide technical and financial resources to entrepreneurs whose ideas have the potential to transform emergency preparedness, detection, and response. Life Science Washington Institute has been selected as one of 13 sites in the DRIVe Accelerator Network to help identify relevant researchers and companies and connect them with the DRIVe team. 
  • InfoEd Global, a provider of software that supports the Electronic Research Administration, has compiled a library of COVID-19 funding opportunities and resources.
  • National Science Foundation Request for SBIR/STTR Phase I Proposals Addressing COVID-19: The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the ability to respond to the COVID-19 crisis. 
  • HHS EZ-BAA for Diagnostics: HHS announced an Easy Broad Agency Announcement (EZ-BAA) for development of COVID-19 diagnostics. Solicitation BAA-20-100-SOL-0002
  • FDA Template for Diagnostics EUA: FDA has developed a COVID-19 Emergency Use Authorization (EUA) template for diagnostic developers, available upon request. Sponsors interested in potential Emergency Use Authorization (EUA) for tests to detect COVID-19 may contact COVID-19 molecular assays for mature, FDA-cleared, widely placed devices are of great interest to the Agency.
  • Gates-Wellcome Trust-Mastercard COVID-19 Therapeutics Accelerator: In March 2020, The Bill & Melinda Gates Foundation, the Wellcome Trust, and Mastercard announced $125 million in seed funding to accelerate the development of therapeutics for COVID-19. The accelerator aims to identify, assess,develop, and scale up treatments.
  • Give BloodBlood Supply Hits Emergency Level Due to Coronavirus Concerns. The increase in COVID-19 cases in Seattle and surrounding counties has led to a shortage in blood products due to a decline in donations. Make an appointment to donate blood.
  • Medical Volunteers Needed: King County Department of Health needs medical volunteers. Medical experts in our community can make a difference now to save lives. Simply email with name, phone, medical background, and availability to be assigned accordingly.
  • Contribute: The King County Medical Society (KCMS) in partnership with the Expedia Group is responding to the growing needs of PPE. Partnering with local garment manufacturers, and professional tailors and sewers, to quickly and effectively produce needed equipment for our frontline health care workers. Donate today just for $25 for a single PPE kit (mask, gown, and cap). If employers have a matching gift program, please contact Nancy L. Belcher at
  • Donations to UW: Gifts are urgently needed to ramp up COVID-19 testing, provide care for the most vulnerable, coordinate the state’s emergency response, support research, and provide lifesaving equipment and resources to ensure the health and well-being of UW patients and clinical teams.
  • UW Medicine Virology: The University of Washington is working to provide clear information by curating a weekly snap shot of current data and information regarding the University of Washington and UW Medicine’s response to COVID-19. 
  • AGC Biologics: Novavax selects AGC Biologics to manufacture Matrix-M™ Adjuvant for COVID-19 Vaccine
  • Bill & Melinda Gates Foundation: Pledging an additional $1.6 billion to the Gavi vaccine alliance for the next five years, plus an additional $100 million specifically for COVID-19 vaccines, preparing to fight the pandemic in low-income countries.